DEXCOM INC
For the period ended Dec 31, 2023. Filed Feb 8, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Feb 8, 2024
DXCM$79.92-1.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
DexCom, Inc.
Consolidated Statements of Stockholders’ Equity
| Common Stock · AdditionalPaid-InCapital · Accumulated Other Comprehensive Income (Loss) · Retained Earnings (Accumulated Deficit) · Treasury Stock · TotalStockholders’Equity | |||||||
|---|---|---|---|---|---|---|---|
| (In millions) · Shares · Amount | |||||||
| Balance at December 31, 2020 | 384.4 | 0.4 | 1,726.5 | 3.2 | (78.2) | (100.0) | 1,551.9 |
| Issuance of common stock under equity incentive plans | 2.9 | — | — | — | — | — | — |
| Issuance of common stock for Employee Stock Purchase Plan | 0.3 | — | 20.3 | — | — | — | 20.3 |
| Tax benefit related to Senior Convertible Notes | — | — | (2.0) | — | — | — | (2.0) |
| Conversions of 2023 Notes | 1.4 | — | 32.6 | — | — | 24.6 | 57.2 |
| Benefit of note hedge upon conversions of 2023 Notes | (1.0) | — | 130.8 | — | — | (130.8) | — |
| Share-based compensation expense | — | — | 113.4 | — | — | — | 113.4 |
| Collaborative research and development fee | — | — | 87.1 | — | — | — | 87.1 |
| Net income | — | — | — | — | 216.9 | — | 216.9 |
| Other comprehensive loss, net of tax | — | — | — | (2.7) | — | — | (2.7) |
| Balance at December 31, 2021 | 388.0 | 0.4 | 2,108.7 | 0.5 | 138.7 | (206.2) | 2,042.1 |
| Issuance of common stock under equity incentive plans | 1.6 | — | — | — | — | — | — |
| Issuance of common stock for Employee Stock Purchase Plan | 0.3 | — | 22.5 | — | — | — | 22.5 |
| Issuance of common stock in connection with achievement of regulatory approval milestone, net of issuance costs | 2.9 | — | (189.3) | — | — | 189.2 | (0.1) |
| Purchases of treasury stock | (6.6) | — | — | — | — | (557.7) | (557.7) |
| Tax benefit related to Senior Convertible Notes | — | — | (0.4) | — | — | — | (0.4) |
| Conversions of 2023 Notes | 0.4 | — | 4.2 | — | — | 13.2 | 17.4 |
| Benefit of note hedge upon conversions of 2023 Notes | (0.3) | — | 33.5 | — | — | (33.5) | — |
| Share-based compensation expense | — | — | 126.5 | — | — | — | 126.5 |
| Capitalization of sales-based milestones | — | — | 152.4 | — | — | — | 152.4 |
| Net income | — | — | — | — | 341.2 | — | 341.2 |
| Other comprehensive loss, net of tax | — | — | — | (12.1) | — | — | (12.1) |
| Balance at December 31, 2022 | 386.3 | $0.4 | $2,258.1 | $(11.6) | $479.9 | $(595.0) | $2,131.8 |
| Issuance of common stock under equity incentive plans | 1.4 | — | — | — | — | — | — |
| Issuance of common stock for Employee Stock Purchase Plan | 0.3 | — | 26.6 | — | — | — | 26.6 |
| Issuance of common stock in connection with achievement of sales-based milestone, net of issuance costs | 3.7 | — | (323.4) | — | — | 323.2 | (0.2) |
| Purchases of treasury stock, including excise tax | (6.3) | — | (0.2) | — | — | (689.0) | (689.2) |
| Tax benefit related to Senior Convertible Notes | — | — | (4.4) | — | — | — | (4.4) |
| Conversions of 2023 Notes | 12.2 | — | (13.1) | — | — | — | (13.1) |
| Benefit of note hedge upon conversions of 2023 Notes | (12.2) | — | 1,496.5 | — | — | (1,490.3) | 6.2 |
| Purchase of capped call transactions, net of tax | — | — | (76.3) | — | — | — | (76.3) |
| Share-based compensation expense | — | — | 150.8 | — | — | — | 150.8 |
| Net income | — | — | — | — | 541.5 | — | 541.5 |
| Other comprehensive loss, net of tax | — | — | — | (5.1) | — | — | (5.1) |
| Balance at December 31, 2023 | 385.4 | $0.4 | $3,514.6 | $(16.7) | $1,021.4 | $(2,451.1) | $2,068.6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.